Navigation Links
Insmed Announces Results of IPLEX(TM) Phase II Trial in Myotonic Muscular Dystrophy
Date:6/25/2009

- Insmed to Evaluate Potential Initiation of Phase II Trial for IPLEX(TM) in MMD Patients with Severe Insulin Resistance -

RICHMOND, Va., June 25 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, today announced results from its exploratory U.S. Phase II clinical trial evaluating IPLEX(TM) (mecasermin rinfabate) in patients with myotonic muscular dystrophy ("MMD"). The randomized, double-blind, placebo-controlled Phase II trial conducted in 13 centers across the U.S. enrolled 69 patients with MMD, for a six-month period. As this was an exploratory trial, a primary endpoint was not pre-defined. The trial explored measures of endurance, using the six-minute walk test, muscle function and strength, cognitive function, gastrointestinal function, pain, quality of life, insulin sensitivity, lipid metabolism, and safety and tolerability of IPLEX(TM).

The results of the trial indicated that IPLEX(TM) did not exhibit a statistically significant improvement in the functional measure of endurance by the six-minute walk test, muscle function, muscle strength, or quality of life in any of the tests utilized in this study. Based on the limited number of subjects enrolled with significant impairments in cognitive function, gastrointestinal function or pain, Insmed was unable to reach any conclusions regarding the effects of IPLEX(TM) on these endpoints.

IPLEX(TM) did, however, demonstrate improvements in standard measures of insulin sensitivity and reductions in fasting glucose, fasting insulin, cholesterol and triglycerides, which is consistent with the expected metabolic profile of insulin-like growth factor. Administration of IPLEX(TM) also resulted in anabolic effects of increased body mass index and higher levels of testosterone. The drug was well tolerated in MMD subjects and d
'/>"/>

SOURCE Insmed Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Insmed CEO Resigns Due to Health Concerns
2. Insmed Announces First Quarter 2009 Financial Results
3. Insmed Regains NASDAQ Compliance
4. Insmed to Host First Quarter 2009 Conference Call
5. Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)
6. Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule
7. Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results
8. Insmed to Host Fourth Quarter and Full-Year 2008 Conference Call
9. Insmed Sells Follow-on Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
10. Insmed to Present at Sanford C. Bernstein Biosimilars Long View Conference
11. Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... Sanofi, a global and ... quarter of 2015. CEO Olivier Brandicourt ... in different businesses. Watch video interview ... Topics covered in the interview include:  ... Performance drivers - Diabetes ...
(Date:7/29/2015)... MONTREAL , July 29, 2015 /PRNewswire/ - BioAmber Inc. ... Laurin , the Company,s Chief Financial Officer has resigned.  ... former Chief Financial Officer who retired in December 2014, ... search for a permanent successor.     Andy ... Mr. Laurin and ensure a smooth transition.  Andy was ...
(Date:7/29/2015)... ... 29, 2015 , ... Brady (NYSE:BRC), a global leader in ... To align chemical container labeling with OSHA’s updated Hazard Communication (HazCom) Standard and ... example of an accurate label, and pictogram uses and meanings. , “With changes ...
(Date:7/29/2015)... ... 2015 , ... The third Medical Innovation Impact Index (MI3) Alert considers FDA ... combinations. The current system received a score of 0 (range -10 to +10) for ... of Fairleigh Dickinson University’s ( FDU ) Rothman Institute of Innovation and Entrepreneurship. ...
Breaking Biology Technology:BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3Brady Announces a New GHS Label Guide 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3
... $17.8 million at June 30 ... September 5, NAPA, Calif., Aug. 14 Senetek PLC ... development,of technologies that target the science of healthy aging, today ... Revenue for the quarter ended June 30, 2008 was $691,000, ...
... P. Loukas, Industry Veteran, Named as CEO ... Named as President and COO, ALTAMONTE SPRINGS, Fla., ... biotechnology company focused on,in-licensing and commercialization of niche oncology ... Chief Executive Officer,effective August 12, 2008. Current President, CEO ...
... Profit Attributable to Shareholders Increased Significantly by ... Fufeng Group Limited,("Fufeng" or "the Group"; HKEx: 546), ... in China, today announces,its interim results for the ... the period under review, driven by the increased ...
Cached Biology Technology:Senetek PLC Reports Second Quarter 2008 Financial Results 2Senetek PLC Reports Second Quarter 2008 Financial Results 3Milestone Biosciences, LLC Further Strengthens Executive Management Team 2Fufeng Announces 2008 Interim Results With Strong Sign of Recovery 2Fufeng Announces 2008 Interim Results With Strong Sign of Recovery 3
(Date:7/27/2015)... SAN JOSE, Calif. , July 27, 2015 ... leading developer of human interface solutions, today announced ... ClearPad ® touchscreen solution for its stylish ... controller for its proven reliability, low power and ... with a wet finger. Huawei designers also required ...
(Date:7/23/2015)... , July 23, 2015 Research ... addition of the "Global Outlook of the ... offering. The global biometrics market ... public and commercial applications owing to the uptake ... witness a transformation that enhances the growth of ...
(Date:7/21/2015)... 21, 2015 Passwords have proven futile ... the recent U.S. Office of Personnel Management breach. ... infosec conundrum, but developers and end-users are concerned ... this dilemma, Biometrics-as-a-Service provider HYPR Corp. announced today ... for third party integration. A ...
Breaking Biology News(10 mins):Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4
... moving closer to understanding how infection is caused by the ... in the high-impact Cell Press journal called Structure , ... at the University of British Columbia, share new knowledge about ... that perform all sorts of functions in the cells of ...
... Boston University School of Medicine (BUSM) have demonstrated in ... protein, reduced binge eating and caused binge eaters to ... in Neuropsychopharmacology , was led by Pietro Cottone, ... the pharmacology and psychiatry departments at BUSM. Binge ...
... bollworm to insect-killing cotton plants involves more diverse genetic ... the journal Proceedings of the National Academy of ... which can harm animals other than the target pests, ... toxins derived from the bacterium Bacillus thuringiensis , ...
Cached Biology News:Discovery increases understanding how bacteria spread: U of A study 2BUSM study shows role of cellular protein in regulation of binge eating 2Trouble on the horizon for GM crops? 2Trouble on the horizon for GM crops? 3Trouble on the horizon for GM crops? 4
... The BioGenex VISION Sytem is a ... comes with proprietary digital imaging and ... digital image acquisition, analysis, archving/retrieval and ... a state-of-the-art digital imaging system that ...
... -mr agarose is specifically for ... endoosmosis, and is recommended for ... weight proteins or complexes that ... of molecular sieving in polyacrylamide ...
... agarose is used for second-dimension SDS-PAGE ... in place in PROTEAN Plus cells. ... to allow monitoring of electrophoresis runs. ... agarose in 1x Tris, glycine, SDS, ...
The Trans-Blot Plus gel and cassette assembly tray is used to hold the Trans-Blot Plus gel holder cassette, buffer, and other materials for the gel and membrane sandwich during their assembly....
Biology Products: